Renaissance Technologies LLC Has $1.46 Million Position in Harvard Bioscience, Inc. (HBIO)

Renaissance Technologies LLC increased its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 5.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 560,500 shares of the medical instruments supplier’s stock after buying an additional 31,300 shares during the period. Renaissance Technologies LLC owned approximately 1.62% of Harvard Bioscience worth $1,457,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Algert Global LLC increased its position in shares of Harvard Bioscience by 17.7% in the first quarter. Algert Global LLC now owns 113,818 shares of the medical instruments supplier’s stock worth $296,000 after buying an additional 17,120 shares during the period. Spark Investment Management LLC increased its position in shares of Harvard Bioscience by 12.8% in the first quarter. Spark Investment Management LLC now owns 116,950 shares of the medical instruments supplier’s stock worth $304,000 after buying an additional 13,250 shares during the period. Essex Investment Management Co. LLC increased its position in shares of Harvard Bioscience by 29.8% in the first quarter. Essex Investment Management Co. LLC now owns 309,582 shares of the medical instruments supplier’s stock worth $805,000 after buying an additional 71,052 shares during the period. Royce & Associates LP increased its position in shares of Harvard Bioscience by 2.9% in the first quarter. Royce & Associates LP now owns 1,557,600 shares of the medical instruments supplier’s stock worth $4,050,000 after buying an additional 44,000 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Harvard Bioscience by 1.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,631,348 shares of the medical instruments supplier’s stock worth $4,242,000 after buying an additional 20,499 shares during the period. 62.24% of the stock is owned by hedge funds and other institutional investors.

Shares of Harvard Bioscience, Inc. (NASDAQ HBIO) traded down 2.70% during trading on Wednesday, hitting $2.70. The stock had a trading volume of 5,895 shares. The firm’s market cap is $94.05 million. Harvard Bioscience, Inc. has a one year low of $2.25 and a one year high of $3.30. The firm’s 50-day moving average is $2.74 and its 200-day moving average is $2.65.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by $0.02. Harvard Bioscience had a negative net margin of 4.37% and a positive return on equity of 1.45%. The business had revenue of $25.21 million during the quarter, compared to analyst estimates of $24 million. Equities research analysts forecast that Harvard Bioscience, Inc. will post $0.13 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “[[title]]” was posted by [[site]] and is the sole property of of [[site]]. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at [[permalink]].

A number of equities analysts have recently issued reports on HBIO shares. ValuEngine downgraded Harvard Bioscience from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. TheStreet raised Harvard Bioscience from a “d+” rating to a “c-” rating in a research note on Monday, July 31st. Finally, Zacks Investment Research raised Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Friday, April 28th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $4.75.

In other news, CEO Jeffrey Duchemin bought 22,000 shares of the business’s stock in a transaction on Monday, June 12th. The shares were bought at an average cost of $2.76 per share, for a total transaction of $60,720.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Earl R. Lewis bought 12,238 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was purchased at an average price of $2.35 per share, for a total transaction of $28,759.30. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 42,950 shares of company stock worth $111,475. Company insiders own 9.80% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.